Êåòî-íàâèãàòîð - ÷èòàòü îíëàéí êíèãó. Àâòîð: Äæîçåô Ìåðêîëà, Äæåéìñ ÄèÍèêîëàíòîíèî còð.¹ 72

÷èòàòü êíèãè îíëàéí áåñïëàòíî
 
 

Îíëàéí êíèãà - Êåòî-íàâèãàòîð | Àâòîð êíèãè - Äæîçåô Ìåðêîëà , Äæåéìñ ÄèÍèêîëàíòîíèî

Còðàíèöà 72
÷èòàòü îíëàéí êíèãè áåñïëàòíî

147. Janakiram NB, Mohammed A, Rao CV. Role of lipoxins, resolvins, and other bioactive lipids in colon and pancreatic cancer. Cancer Metastasis Rev. 2011 Dec; 30 (3–4): 507–523.

148. Gonzalez MJ, Schemmel RA, Gray JI, et al. Effect of dietary fat on growth of MCF-7 and MDA-MB231 human breast carcinomas in athymic nude mice: relationship between carcinoma growth and lipid peroxidation product levels. Carcinogenesis. 1991 Jul; 12 (7): 1231–1235.

149. Gonzalez MJ, Schemmel RA, Dugan L, Jr., et al. Dietary fish oil inhibits human breast carcinoma growth: a function of increased lipid peroxidation. Lipids. 1993 Sep; 28 (9): 827–832.

150. Hudson EA, Beck SA, Tisdale MJ. Kinetics of the inhibition of tumour growth in mice by eicosapentaenoic acid-reversal by linoleic acid. Biochem Pharmacol. 1993 Jun 9; 45 (11): 2189–2194.

151. Conklin KA. Dietary polyunsaturated fatty acids: impact on cancer chemotherapy and radiation. Altern Med Rev. 2002 Feb; 7 (1): 4–21.

152. Òàì æå.

153. Òàì æå.

154. Òàì æå.

Ãëàâà ñåäüìàÿ

1. Ogden CL, Carroll MD, Kit BK, et al. Prevalence of obesity in the United States, 2009–2010. NCHS data brief. 2012 Jan: (82) 1–8.

2. Yki-Jarvinen H. Fat in the liver and insulin resistance. Ann Med. 2005; 37 (5): 347–356.

3. Jung SH, Ha KH, Kim DJ. Visceral Fat Mass Has Stronger Associations with Diabetes and Prediabetes than Other Anthropometric Obesity Indicators among Korean Adults. Yonsei Med J. 2016 May 1; 57 (3): 674–680.

4. Sheth SG, Chopra Sanjive. Epidemiology, clinical features, and diagnosis of nonalcoholic fatty liver disease in adults [Èíòåðíåò]. UpToDate. 2018. Äîñòóïíî ïî àäðåñó http://www.uptodate.com/contents/epidemiology-clinical-features-anddiagnosis-of-nonalcoholic-fatty-liver-disease-in-adults.

5. Vernon G, Baranova A, Younossi ZM. Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment Pharmacol Ther. 2011 Aug; 34 (3): 274–285.

6. Williams CD, Stengel J, Asike MI, et al. Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study. Gastroenterology. 2011 Jan; 140 (1): 124–131.

7. Menke A, Casagrande S, Geiss L, et al. Prevalence of and trends in diabetes among adults in the United States, 1988-2012. JAMA. 2015 Sep 8; 314 (1): 1021–1029.

8. Lopategi A, Lopez-Vicario C, Alcaraz-Quiles J, et al. Role of bioactive lipid mediators in obese adipose tissue inflammation and endocrine dysfunction. Mol Cell Endocrinol. 2016 Jan 5; 419: 44–59.

9. Òàì æå.

10. Claria J, Nguyen BT, Madenci AL, et al. Diversity of lipid mediators in human adipose tissue depots. Am J Physiol Cell Physiol. 2013 Jun 15; 304 (12): C1141–1149.

11. Claria J, Dalli J, Yacoubian S, et al. Resolvin D1 and resolvin D2 govern local inflammatory tone in obese fat. J Immunol. 2012 Sep 1; 189 (5): 2597–2605.

12. Lopategi A, Lopez-Vicario C, Alcaraz-Quiles J, et al. Role of bioactive lipid mediators in obese adipose tissue inflammation and endocrine dysfunction. Mol Cell Endocrinol. 2016 Jan 5; 419: 44–59.

13. White PJ, Arita M, Taguchi R, et al. Transgenic restoration of long-chain n-3 fatty acids in insulin target tissues improves resolution capacity and alleviates obesity-linked inflammation and insulin resistance in high-fat-fed mice. Diabetes. 2010 Dec; 59 (12): 3066–30673.

14. Neuhofer A, Zeyda M, Mascher D, et al. Impaired local production of proresolving lipid mediators in obesity and 17-HDHA as a potential treatment for obesity-associated inflammation. Diabetes. 2013 Jun; 62 (6): 1945–1956.

15. Hellmann J, Tang Y, Kosuri M, et al. Resolvin D1 decreases adipose tissue macrophage accumulation and improves insulin sensitivity in obese-diabetic mice. FASEB J. 2011 Jul; 25 (7): 2399–2407.

16. Lopategi A, Lopez-Vicario C, Alcaraz-Quiles J, et al. Role of bioactive lipid mediators in obese adipose tissue inflammation and endocrine dysfunction. Mol Cell Endocrinol. 2016 Jan 5; 419: 44–59.

17. Òàì æå.

18. Guyenet SJ, Carlson SE. Increase in adipose tissue linoleic acid of US adults in the last half century. Advances in Nutrition. 2015 Nov 1; 6 (6): 660–664.

19. Surette ME, Koumenis IL, Edens MB, et al. Inhibition of leukotriene synthesis, pharmacokinetics, and tolerability of a novel dietary fatty acid formulation in healthy adult subjects. Clin Ther. 2003 Mar; 25 (3): 948–971.

20. James MJ, Gibson RA, Cleland LG. Dietary polyunsaturated fatty acids and inflammatory mediator production. Am J Clin Nutr. 2000 Jan; 71 (1 Suppl): 343s–8s.

21. Manole, Bogdan A. “Effect of Alpha-Linolenic Acid on Global Fatty Oxidation in Adipocytes and Skeletal Muscle Cells” [honors thesis project]. University of Tennessee; 2011.

22. Ikemoto S, Takahashi M, Tsunoda N, et al. High-fat diet-induced hyperglycemia and obesity in mice: differential effects of dietary oils. Metabolism. 1996 Dec; 45 (12): 1539–1546.

23. Hill JO, Peters JC, Lin D, et al. Lipid accumulation and body fat distribution is influenced by type of dietary fat fed to rats. Int J Obes Relat Metab Disord. 1993 Apr; 17 (4): 223–236.

24. Flachs P, Rossmeisl M, Kuda O, et al. Stimulation of mitochondrial oxidative capacity in white fat independent of UCP1: a key to lean phenotype. Biochim Biophys Acta. 2013 May; 1831 (5): 986–1003.

25. Flachs P, Horakova O, Brauner P, et al. Polyunsaturated fatty acids of marine origin upregulate mitochondrial biogenesis and induce beta-oxidation in white fat. Diabetologia. 2005 Nov; 48 (11): 2365–2375.

26. Hensler M, Bardova K, Jilkova ZM, et al. The inhibition of fat cell proliferation by n-3 fatty acids in dietary obese mice. Lipids Health Dis. 2011 Aug 2; 10: 128.

27. Ruzickova J, Rossmeisl M, Prazak T, et al. Omega-3 PUFA of marine origin limit diet-induced obesity in mice by reducing cellularity of adipose tissue. Lipids. 2004 Dec; 39 (12): 1177–1785.

28. Spalding KL, Arner E, Westermark PO, et al. Dynamics of fat cell turnover in humans. Nature. 2008 Jun 5; 453 (7196): 783–787.

29. Azain MJ. Role of fatty acids in adipocyte growth and development. J Anim Sci. 2004 Mar; 82 (3): 916–924.

30. Hutley LJ, Newell FM, Joyner JM, et al. Effects of rosiglitazone and linoleic acid on human preadipocyte differentiation. Eur J Clin Invest. 2003 Jul; 33 (7): 574–581.

31. Alvheim AR, Malde MK, Osei-Hyiaman D, et al. Dietary linoleic acid elevates endogenous 2-AG and anandamide and induces obesity. Obesity (Silver Spring). 2012 Oct; 20 (1): 1984–1994.

Âåðíóòüñÿ ê ïðîñìîòðó êíèãè Ïåðåéòè ê Îãëàâëåíèþ Ïåðåéòè ê Ïðèìå÷àíèþ